| Jul 9 |
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
|
| Jul 1 |
uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 52%
|
| Jul 1 |
Genezen to buy uniQure's gene therapy operations in Lexington
|
| Jul 1 |
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
|
| Jul 1 |
Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA
|
| Jul 1 |
UniQure, with sale of plant, outsources Hemgenix manufacturing
|
| Jun 3 |
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
|
| May 9 |
uniQure First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
| May 7 |
uniQure GAAP EPS of -$1.36 misses by $0.09, revenue of $8.49M beats by $2.18M
|
| May 7 |
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
|
